We have demonstrated that the model used in this study has a higher number of positive cells of immune cell markers augmenting immune rejection of tumor cells than immune tolerance of tumor cells, i.e. a higher number of positive cells for CD8α than CD2 and CD3 and a higher number of positive cells for CD68 than CD163. This evidence concerns the gene CD2 and neoplasm.